Over the past 18 months, our partnered research programs achieved the following:   Received an upfront payment of $40 million from Celgene upon signing an option to license worldwide rights to drugs developed under the collaboration that are directed to two of the four mutually selected discovery targets. Array is entitled to receive, for each drug licensed to Celgene, potential milestone payments of approximately $200 million, if certain discovery, development and regulatory milestones are achieved and $300 million if certain commercial milestones are achieved, as well as royalties on net sales. Array will retain all rights to the other programs.   Received $5 million in payments from AstraZeneca for achieving clinical milestones on the MEK for cancer program.   InterMune, Inc. initiated patient dosing in January 2007 on a Phase 1a clinical trial with ITMN-191, an orally available Hepatitis C virus (HCV) protease inhibitor, triggering a milestone payment of $500 thousand.   Received a milestone payment from Eli Lilly and Company for dosing the CHK-1 inhibitor, IC83, in a Phase 1 clinical trial. Scientists at Array and ICOS Corporation, which was acquired by Eli Lilly in 2007, collaborated to invent IC83.   Entered into a license agreement with VentiRx Pharmaceuticals Inc., granting VentiRx exclusive worldwide rights to Array’s toll-like receptor (TLR) program. Array received an equity stake in VentiRx, a privately held company, as well as an up-front payment, and is entitled to receive potential milestone payments and royalties on product sales. Array retains the option to acquire a 50% ownership position in all VentiRx clinical oncology products developed under this agreement.

Partnered Research and Development
We have research partnerships with leading pharmaceutical and biotechnology companies for which we design, create and optimize drug candidates, and conduct preclinical testing across a broad range of therapeutic areas. In certain partnerships, we also perform process research and development, and manufacture clinical supplies. These partnerships involve either continued research and development on programs we have out-licensed or drug discovery and development on targets selected by our partners. These collaborations provide research funding and, in a number of our current agreements, up-front fees, milestone payments and/or royalties based upon the success of the program. Our largest partners, from whom we are receiving research funding or have the potential for future milestones or royalties, include Celgene Corporation, AstraZeneca, Genentech, InterMune, Ono Pharmaceutical Co., Ltd., Amgen Inc., Eli Lilly and Company (ICOS Corporation), Japan Tobacco Inc., and Takeda Pharmaceutical Company, Ltd.

Our research team’s productivity has produced more early-stage discovery assets than we can develop internally. During the next three years, we intend to out-license certain of these assets through research partnerships of higher value than our traditional collaborations. We believe this strategy will create opportunities for greater financial upside while continuing to provide a revenue stream and will allow us to maintain a critical mass of scientists required for a world-class research platform.

If you are interested in learning more about our proprietary pipeline or collaborating with Array, please contact our Business Development group:

Phone: 303.381.6611
E-mail: bd@arraybiopharma.com